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ABSTRACT
DESIGN OF AN EFFECTIVE AND TIMELY PRODUCT DEVELOPMENT
PROCESS FOR MEDICAL DEVICES
by
Jean Benoit Almonor
Effective product development process is one of the most critical issues facing
medical devices manufacturing today. There is a need to search for ways to improve or
solve the cross organization and company boundaries to enhance the faster release of new
medical products to the market. This thesis presents an integrated set of perspectives on
the process of new product development of medical devices with dual goals of achieving
marketing speed and meet customer satisfaction.
The Attribute Driven Specifications approach described in this thesis, is one of the
most valuable tools in the approach to effective product development in medical devices.
This thesis aims to promote effective management of product design and
development of medical devices by addressing the inherent complexity and operational
reality of the development process of medical devices. Also presented are approaches to
product design and development employed by some successful medical device industries.
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CHAPTER 1
INTRODUCTION
1.1 The Need for New Products
In this era of global competition and accelerating product life cycles, the need to get new
products to market faster is more compelling than ever. There is an old saying, "Time is
Money", this statement couldn't be any truer in the present age. Time-to-market is
crucial as competitive pressure increases. What was once considered fast development is
now a commonplace.
New products determine the future of manufacturing companies. Without well-
designed, effectively developed new products, a company's prosperity is limited. A lack
of introduction of successful new products can even threaten companies whose prior
product success was legendary. Wang Laboratories' information-based office systems
and Polaroid's instant photography are two examples. Counting on the continued
rewards from existing products can be a recipe for failure. Although a stream of
incremental improvements to existing products may prevent disaster, it is usually not
long before competitor initiatives and shifting customer needs make a firm's existing
products obsolete.
Companies try to respond to market changes and competitive pressure by
introducing new products, but this requires more thought and effort than usually invested
by companies. Product design and development is an ongoing company activity and
should be consistent with the overall business strategy of a company.
In the past several years, rapid product development has become increasingly
popular through industry. With this rise in popularity we find some companies that are
pursuing rapid development simply because they believe that fast time to market is
universally good. Fast time-to-market is worth money, sometimes a great deal of money,
but it is not universally so. The only way to determine which actions are appropriate in
pursuing development speed is to know what cycle time is worth in financial terms.
Since your competitors are also getting faster, a sloppy approach to pursue rapid
development will become more expensive.
This thesis provides the necessary tools to achieve more efficient product
development cycle time in the medical devices industry. This thesis strives to present a
balanced and integrated view of product development. Although it goes into depth about
the regulatory requirements for medical devices, the greatest gains are to be made by how
integrated disciplines are used to contribute in an effective manner in the product
development process. The primary goal is to describe the basic product development
process for medical devices and to provide techniques such as the approach to the
Attribute Driven Specifications described in chapter 4, as a basis for improvement. Also
presented is a practical approach to the development process. This thesis presents an
integrated set of perspectives on the process of new product development for medical
devices, with an emphasis on new ways of achieving speed to market and meet customer
satisfaction.
31.2 Concurrent Engineering
The overwhelming conclusion of everyone who has researched into Concurrent
Engineering (CE) is that the bulk of the leverage occurs in the product's conceptual
design. Here we make the basic design choices that will determine a product's possible
manufacturing processes. We can view our design choices as having to meet the needs of
both engineering and manufacturing. When a design fails to meet the needs of either of
these groups, rework is required. The key difference in rework that comes from
manufacturing issues is that it is expensive and late in comparison to rework originating
from engineering issues.
By increasing the number of design choices that meet the needs of manufacturing
in advance we reduce this rework. The problem with most design processes is that they
first design to meet the needs of engineering and then assess manufacturability. This
means that the needs of manufacturing are poorly served until late in the design process.
A better approach is to address the needs of manufacturing and engineering
simultaneously. This reduces the number of design decisions that fails to meet the needs
of manufacturing.
Sports analogies have been widely used to distinguish between sequential and
simultaneous approaches. The more traditional sequential approach is portrayed as a
relay race, in which only one player runs at a time and a baton is passed in one direction
from one runner to his or her successor. If any one runner stumble, or if the hand-off is
bobbled, the entire effort is delayed. Simultaneous engineering, in contrast, is likened to
a game of rugby. Here, the entire team runs down the field at the same time, repeatedly
4passing the ball and forth among players. Since the two sports events are different, the
analogies that can be drawn between them are limited, but the image is clear.
1.3 What is Concurrent Engineering?
Concurrent Engineering (CE) is also known as simultaneous or parallel engineering. It
represents a structured, logical framework, which supports a systematic approach to the
integrated. Figure 1 shows an example of CE or parallel engineering.
This method is intended to ensure that developers consider all elements of the
product life cycle from conception through to final disposition, including quality, cost
schedule, and user requirements. CE focuses on customer satisfaction and teamwork as
well as on design for manufacturing, design for assembly and quality issues.
CE is very much a team-management, people, communications, sound technology
and culture issue. It is about thinking of the total design and manufacturing cycle, and
implementing it using appropriate technologies and excellent people equipped with multi
disciplinary skills.
The heart of the problem is that engineers in design, manufacturing, medical,
quality assurance, and R&D do not speak the same language. Most of the obstacles are
cultural and organizational. What this technology provides is fundamentally the excellent
communications systems that the small family business always had, as well as new
methods and tools for creating, analyzing, testing and implementing products that the
customers need.
5Concurrent or Simultaneous Engineering, or Complete
Parallel Processing
Figure 1 The Principal Activities of the Commence Parallel and Concurrent Engineering
Source: Paul G. Ranky — Concurrent/Simultaneous Engineering 1951
61.4 Product Reliability is Key for Concurrent Engineering
in the Development Process of Medical Devices
Reliability engineering is key to concurrent engineering through product development
teams. Reliability engineering is one of these essential links, since reliability, as a
product attribute, is an essential ingredient to the success of any product. Customers
expect their products to work on demand. As devices functionally become more
intricate, concerns arise regarding efficacy, safety and reliability. Both the user and the
patient want the device to operate as specified, perform in a safe manner, and continue to
perform over a long period of time without failure. To be successful, the designer and
manufacturer of medical devices must ensure that all devices meet these requirements.
Reliability assurance is an integral part of the product development process and of
problem solving activities related to manufacturing and field failure. Reliability
assurance is essential to the success of any medical device company. It helps develop a
more profitable product, contributes to a more satisfied customer base, reduces the risk of
liability and builds confidence in meeting the requirements of standards and regulatory
organizations. Reliability is a characteristic that describes how good a device really is. It
is a measure of the dependability of the device. It is a characteristic that must be planned
for, designed and manufactured into the design. The inclusion of reliability in
manufacturing is important, because no matter how well a device is designed, it will not
be a success unless it is manufactured and serviced reliably.
When developing a medical device, it is of utmost importance to design the
device to operate according to specifications, without failure for a maximum period of
time. To do this, failure must be analyzed as to whether its occurrence will allow the
device to keep operating at a safe level, or whether the device should be shut down to
avoid potential harm to the patient or the user.
If a product is found to be defective in the hand of the user the manufacturer may
be liable for the harm that the product causes. This could have significant consequences.
Table 1 shows some of the liability suits filed in the federal district court in regards to
product liability cases.
Table 1 Product Liability Suits Filed in Federal District Courts
Source: Administrative Office of U.S. Courts
Product Liability suits filed in
Federal District Courts
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81.5 The Impact of Regulations
on Product Development of Medical Devices
Although there are many good tools to use when developing new product, there are also
some problematic areas in the development process. One of these is the dilemma that
occurs in writing specifications. For Medical Device industries, which are regulated by
Food and Drug Administration, certain levels of quality are required, such as
requirements of Good Manufacturing Practices (GMP). The Quality Systems (QS) in the
current GMP require that domestic or foreign manufacturers have quality system for the
design and production of medical devices intended for commercial distribution in the
United States. The regulation requires that various specifications and controls be
established for devices; that they are manufactured under a quality system; that finished
devices meet these specifications; that devices be correctly installed, checked and
serviced; that quality data be analyzed to identify and correct quality problems and that
complaints be processed. Thus the QS regulation helps assure that medical devices are
safe and effective for their intended use. The FDA monitors device problem data and
inspects the operation and records of device developers and manufacturers to determine
compliance with the GMP requirements in the QS regulation.
The medical device QS regulation requires an umbrella quality system intended to
cover the design, production, and distribution of all medical devices. In most cases, it is
left to the manufacturer to determine the best methods to attain quality objectives. In
some cases, however, the QS regulation does specify the particular type of method to be
used such as written procedures or written instructions.
91.6 The Food and Drug Administration
The Food and Drug Administration's (FDA) job is to see that the food we eat is safe and
wholesome, the cosmetics we use won't hurt us, the medicines and medical devices we
use are safe and effective and that radiation-emitting products such as microwave ovens
won't do us harm. FDA also ensures that all of these products are labeled truthfully with
the information that people need to use them properly. FDA is the United States' oldest
consumer protection agency. FDA is a public health agency, charged with protecting
American consumers by enforcing the Federal Food, Drug, and Cosmetic Act and several
related public health laws.
If a company is found violating any of the laws that FDA enforces, FDA can
encourage the firm to voluntarily correct the problem or to recall a faulty product from
the market. A recall is generally the fastest and most effective way to protect the public
from an unsafe product. When a company can't or won't correct a public health problem
with one of its products voluntarily, FDA has legal sanctions it can bring to bear. The
agency can go to court to force a company to stop selling a product and to have items
already produced seized and destroyed.
1.7 What is a Medical Device?
There are as many different definitions for a medical device as there are regulatory and
standards organizations. Section 201(h) of the Federal Food, Drug, and Cosmetic Act
defines a medical device as an instrument, apparatus, implement, machine, contrivance,
implant, in vitro reagent, or other similar or related article including any component part,
or accessory, which is
o Recognized in the official National Formulary, or the United States Pharmacopeia, or
any supplement to them.
o Intended for use in the diagnosis of disease or other conditions, or in the cure,
mitigation, treatment, or prevention of disease, in man or other animals.
o Intended to affect the structure or any function of the body of man or other animals
Which does not achieve any of its principal intended purposes through chemical action
within or in the body of man or other animals and which is not dependent upon being
metabolized for the achievement of any of its principal intended purposes
The Medical Device Amendments of 1976 expanded the definition to include:
o Device intended for use in the diagnosis of conditions other than disease, such as
pregnancy
o In vitro diagnostic products, including those previously regulated as drugs.
Medical devices are classified and regulated according to their degree of risk to
the public. Devices that are life-supporting, life-sustaining or implanted, such as
pacemakers, must receive agency approval before they can be marketed. FDA's
investigation does not end when a drug or device is approved for marketing; the agency
collects and analyzes tens of thousands of reports each year on drugs and devices after
they have been put on the market to monitor for any unexpected adverse reactions.
Medical devices are important part of health care. Yet they are an extraordinarily
miscellaneous category of products. The term "medical device" includes such
technologically simple articles as ice bags and tongue depressors on one end of the
expansion and very sophisticated articles such as pacemakers and surgical lasers on the
other. Figures 2, 3 and 4 illustrate some currently marketed medical devices by Becton
Dickinson VACUTAINER Systems. These tubes are used to collect blood for diagnosis
of the patients and allow the doctor to provide proper treatment.
Figure 2 Becton Dickinson VACUTAINER® K3 EDTA Tube
Figure 3 VACUTAINER® Evacuated Blood Collection Tube
© Becton Dickinson and Company, 1995
Figure 4 VACUTAINER® Next Generation Evacuated Blood Collection Device
0 Becton Dickinson, 1997
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Perhaps it is this diversity of products coupled with the delicate number of
different devices that makes the development of an effective and efficient regulatory
scheme a unique challenge for domestic and international regulatory bodies.
The complexities of the FDA's regulations, along with the current regulatory, make the
decisions concerning the medical devices approval strategy all more important. Although
medical devices may vary in size, weight, complexity, and functionality, they have one
thing in common. All must be safe and effective for their intended use. To be successful
in this business, the device is to be highly reliable. Making devices safe, effective and
reliable begins at the earliest stages of product design and is a continuous process through
production and maintenance.
Safety must always be the most important consideration in designing and
developing a medical device. A device must never function or malfunction in a way that
will cause harm to either the user or the patient. Safety is not optional, nor can it be
attained solely through standards compliance; it must be integrated in the design.
1.8 The Trend for Medical Devices
Medical care has become increasingly dependent on technology, and medical devices are
the drivers of that trend. The modern hospital is full of complicate machinery. Tens of
thousands of Americans depend upon artificial body parts for survival and to improve the
quality of their lives, from hips to intraocular lenses to heart pacemakers. Even doctors'
offices are full of new devices. Physicians use lasers to remove cataracts without the
need for hospitalization. The allure of medical innovation is powerful, holding out the
possibility of a perfect outcome, an amelioration of pain and possibly a postponement of
1 5
death. At the current rate of innovation, an analyst cun-ently projected, by the year 2000
close to 100,000 new or enhanced medical devices will have been introduced into the
marketplace. Table 2 illustrates the value of this industry and table 3 shows that over
$20 billion in 1989 are being spent on R&D for the innovation of new medical devices.
Table 2 Forecast Health Spending
Source: MS. Freeland et. Al., Health Care Financing Review 6
Table 3 National Support for Health R&D
Source: NIH Data Book, no 90-1261 (December 1989)
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National Support for Health R&D
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1.9 Background
There has been numerous approaches to cycle-time reduction for new product
development over the years. Martin Mathelier, a graduate from New Jersey Institute of
Technology (NJIT) discussed in his master thesis (January 1994) Concurrent
Engineering and Design for Manufacturing in the Medical Device Industry" the principle
of an axiomatic approach to manufacturing. He described how techniques such as
Quality Function Deployment (QFD) could be used in the product development of
Medical Devices. His thesis applied these tools in Concurrent Engineering (CE) to show
success in the product development of Medical Devices.
In his 1951 book titled "Concurrent/Simultaneous Engineering", Paul Ranky
used CE as key to the success of product development where he defines CE as a team
management, people, communications, sound technology, and a culture issue. He
emphasizes on thinking of the total design and manufacturing cycle, and implementing it,
using appropriate technology and excellent people equipped with multi disciplinary
skills.
Arthur D. Little, a consultant for medical device products (ref. 1998, Directory to
Medical Products Manufacturing Consultant) also use the integrated approach; he works
with the customer and coordinates team effort to create innovative product concepts and
identify the best design. The team applies comprehensive product development process
methodology, from market analysis to rapid prototyping to Design for Manufacturing and
Assembly to manufacturing system design. The result of that process was the release of a
33 mm trocar which was develop in less than a year, met all qualities standards, and cost
far less to produce than initial budget targets.
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Medical device development is a complex process that requires the careful
integration of diverse disciplines, technical activities, standards, regulatory requirements,
and administrative project controls. The need for systematic approaches to product
development and maintenance is necessary to ensure a safe and effective device for the
user and patient, an economical and competitive success for the manufacturer, and a
reliable, cost-effective investment for the user.
CHAPTER 2
CURRENT PRODUCT DEVELOPMENT PROCESSES FOR MEDICAL
DEVICES
2.1 From Conceptual Phase to the Release Phase
of Medical Devices Product Development Cycle
New medical device products come to the market through a process that first transforms
ideas and concepts into working prototypes through detailed design and engineering, then
tests and refines them to meet regulations, and finally prepares the product design and
factories for commercial operation. The schematic of the development process illustrated
in figure 5 defines the way in which many medical devices industries propose and select
concepts, and how these concepts converge to a specific product definition, design, and
release to the market. The development process as defined in this chapter lays out the
pattern of how to release a medical device product to the market.
The process described in this chapter provides tools and guidelines on how to
develop and release medical device products. The Product Development Notification
(PDN) process discussed is a very important part of the development process. It informs
the organization of the new product that is about to be developed and released for sale.
Furthermore, the Core Team approach discussed in this chapter is a good example of
concurrent engineering.
19
Figure 5 Overview of Current Product Development Process for Medical Devices
20
21
2.2 The Development Process
2.2.1 How do you Get a Product Concept?
All new products start with a concept. If you don't already have a concept for a new
product, then you will need to develop one. New product ideas are not simply born.
Most good concepts begin with either a perceived or a measured need. New product
ideas come from examining the needs of hospitals, nurses, physicians and other medical
professionals as well as from sales and marketing personnel. It is important to talk with
physicians and nurses to determine what their problems are and how they can be
addressed. These problems generally represent good product opportunities.
There usually are several needs from which to choose. The one with the greatest
impact on your customer is usually a good one to pick. After all, they are the ones that
are going to buy your new product/service. Once the need has been identified, it is better
to capture it in writing as clearly and concisely as possible. It is also a good practice to
describe the need and why it exists, be sure to describe who the customer is.
Now, identify a customer need that you are not currently satisfying. Although
you may have an idea of what is important to your customers, make sure you ask them
for suggestions. Once you have thoroughly defined the need, summarize it and post it
where most of your product development work will be conducted. Review the
summarized need regularly as you develop your new product. This will keep you
focused on the customer throughout the development process.
In addition to your customers and employees, there are other sources for new
product ideas. Patent search is another good way of getting new ideas;
The Government-owned patents are a good way to start; call your local Small Business
Administration (SBA) office or write to the U.S. Patent Office. The Patent Abstract
Bibliography lists NASA-owned patents and can be ordered from the National Technical
Information Service (NTIS). AEC-NASA Technical Briefs are 1 or 2 page descriptions of
ideas, patents, concepts available to the general public. Government Reports
Announcements and Indices are current awareness announcements. Both are also
available from NTIS.
Private granted patents could be found in The Official Gazette published by the
U.S. Patent Office on a weekly basis. The patent attorneys are also good resources.
Large companies often have hundreds of patents for products that they haven't
commercialized for one reason or another. Investigate patents held by large companies in
your industry. They may be willing to license patent that could be a gold mine for you.
2.2.2 The Project Proposal/Approval Cycle
The product development process begins when an idea for a new product is presented to
upper management. This latter is a cross-functional team made up of representatives of
the senior management committee who determine the strategic business decisions for the
project. If the idea seems promising, management instructs representatives from various
areas within the company (e.g., marketing, engineering, medical, regulatory affairs, and
manufacturing) to investigate whether it is feasible to develop the product.
Working along with others, representatives from the various departments attempt
to determine the basic resources and requirements needed to complete the project
successfully, and decide whether the benefits of producing it outweigh the risks. After
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they have completed their research, department members produce a project proposal; a
document recommending whether or not to develop the product and various conditions
related to its manufacture. Management reviews the document and decides whether to go
ahead with the project or cancel it. Once management decides that a project is worth
pursuing, planning the development process can actually begin.
2.2.3 The Core Team Approach
Of all decisions management makes, none is more crucial to success than choosing a
team leader. A strong leader will be able to overcome many other shortcomings and
imperfect decisions, but a mediocre one will be puzzled by even small obstacles. The
leader is often the buffer insulating the team from inappropriate management practices
that run uncontrolled in the rest of the company. It is important to pick a leader carefully
and announce the choice publicly. Everyone should know exactly who is responsible for
successful completion of the project and what authority he or she has been granted by
management. Selecting a good overall core team leader is crucial to the success of
planning the project.
The role of a leader is to maintain overall responsibility and leadership for the
project. The leader will set the tone for the project by providing motivation to the
members of the team and keeping the team focussed on the plan. The leader has to set
high expectations, take risks ands create team excitement about their participation on the
project.
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The Core Team leader holds the ultimate responsibility for the course of the
product's development. Committee management of the project will not work; as the
saying goes, "When everybody is responsible, nobody is responsible."
The core team leader should hold regular meetings with the project team to track the
status of project planning. It is important not to underestimate the value of these
meetings; they are the glue that holds various project activities together. Minutes of
meetings should be published and distributed to notify team members of pending action
items and provide project status information.
Once the team leader has been selected, the leader should recruit the team
members. This is most commonly done by preparing a list of desired team members and
negotiating with the functional owners of these resources for their time.
Core Team Members coordinate the project activities for their particular
functions. They act as pipelines for communicating both functional needs into the
development effort and project requirements back into the functional organization. Core
Team members also manage the project resources for the activities that they have
responsibility for. The purpose of the Core Team is to bring the necessary expertise to a
project from a greater resource pool on an as-needed basis. An unlimited amount of
personnel can serve on the project team depending upon the complexity. An illustration
of a Core Team structure diagram is shown figure 6. With the Core Team approach,
senior management makes the critical decisions regarding the product, but the Core Team
members make all the implementation or tactical decisions necessary to develop the
product.
Graphic/Packaging
R&D
Sales
Marketing
Finance
PIC
Product Development
Manufacturing Engineer
CORE Team Leader
WW Regulatory
Medical
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Figure 6 Core Team
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2.2.4 The Importance of the Project Plan
The first thing the Core Team leader and Core Team members must do is to draw up a
systematic, overall project plan that identifies general terms, the network of activities,
personnel, and resources that will be involved in the design and development process.
A project plan organizes and documents the development process and breaks it
down into manageable chunks. Conceptually, project stages are distinct from one
another, and ideally team members complete the activities in one stage before moving on
to the next. In practice, however, activities in different stages sometimes overlap or are
carried out concurrently. Also, activities in a given stage (for example a verification
procedure) are sometimes repeated to refine the accuracy of the results.
To create the overall project plan, the Core Team leader and team members must
look at the entire design and development process and decide what tasks need to be
accomplished, in what order, how long they will take, which individuals and departments
are needed to accomplish them, the best way to make use of people's time, and a general
estimate of how much the process will cost. They must answer the same kinds of
questions about materials and resources, and plot all these variables along a time line.
They then select appropriate members for the project team, which includes people from
almost every department in the company.
The overall project plan established the "big picture" of product development; the
degree of detail in the overall plan varies depending on the product, the size of the
company, its experience in developing products of this type, and so on. Later, as the
project takes shape and the project team gets a better feel for the product, planning in
getting detail is necessary, usually related to the completion of specific tasks.
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For example, the overall planning phase might establish that the staff needs to
begin planning for verification testing soon after actual design work begins, so that when
product prototypes are developed, the test procedures are in place and there are no
unnecessary delays or holdups. Later, in the actual design phase, specific details about
verification testing can be altered if necessary.
Deciding how broad the scope of a project plan should be and how much detail it
can specify is one of the biggest challenges facing project management. The more
planning that can be done early on, the easier it is to anticipate potential problems and
minimize delays further down the line. The trade-off, however, is that those decisions
made too soon may have to be changed, possibly wasting time and resources.
To help deal with these concerns, some type of planning procedure or set of flow
diagrams (such as the program evaluation and review technique (PERT)), maybe used to
create a project schedule and keep track of project progress. These procedures can take
the form of manuals and books, and a number of software applications for desktop
computers are also available to make preparation of the design plan and project
management easier.
Planning procedures encourage a project team to take a disciplined approach to
design planning by presenting a structured set of questions that must be answered. They
enable project management to create standard operating procedures that can be applied to
all areas of product development as the project proceeds.
Developing an overall project plan is a major undertaking and can require
considerable time. The Core Team must decide whether it is wise to begin actual design
work before the overall project plan is completed. The R&D and engineering
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departments will sometimes do preliminary research, before a project plan is finished, to
test the feasibility of an element in the project proposal, especially if a new, unproven, or
high-risk technology is involved. In some cases, the core team may deem it is important
to get started with the design quickly to stay ahead of the competition, or to take
advantage of a marketing opportunity. Other companies, however, take a hard line and
refuse to begin work until the project plan is completed and management signs off on it.
Before the project plan is submitted to management, the Core Team leader should
hold a final meeting with everyone on the team to ensure that the plan is completed to his
or her satisfaction. Some companies develop a checklist of critical items that must be
addressed before the plan is approved. When management has approved a
comprehensive plan outlining the entire project, planning for the actual design work of
product development can proceed.
2.2.5 Product Development Notification Process
Product Development Notification (PDN) is a cross functional communication process
that is designed primarily for engineers and scientists to detail the product and process
introductions, product design or product/process changes that impact product
performance. The way the PDN works is as follows:
The originator filled out the PDN form and addresses it to the Medical Department.
The PDN coordinator from the Medical department distributes copies of the PDN to
the Medical Director, Division Quality Assurance (QA), Regulatory Affairs (RA),
R&D, Manufacturing, Marketing etc. for review.
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The Medical Director is a expert in physiology and medical assigned to a particular
division to provide medical, technical and ethical oversight. He provides definition of
evaluations necessary to document product safety and efficacy for all PDNs.
2.2.6 Obtain PDN Requirements
If the PDN is for the development of a new medical device, (e.g. a blood-evacuated tube)
the Medical Director knows what is required to make a quality blood-evacuated tube,
would require the originator to perform clinical functional testing on the tube before
releasing it to the market. This may include testing for a variety of clinical analytes or
the use of products during phlebotomy procedures. The Quality department could require
that Design and Process Failure Mode Effect Analysis (FMEA) be performed to ensure
that the design is safe before going out to the customer. Also, they could require that a
process validation be conducted to assure that the process would be able to make
products consistently within specifications. The Marketing department could require that
an End User Assessment should be conducted before product launch. The R&D
department could be required to perform different material testing, to ensure that the
materials used are safe and will not leach into the blood sample or interfere with
performance; the R&D department could require that a product validation is to be
conducted, shipping tests are to be performed and functional engineering tests to be done
before release. The regulatory Department will dictate the labeling content, FDA
notification, 510 (k) requirements, etc.
Upon receipt of the PDN form the coordinator, the manager of that department
could additionally chose to circulate the PDN to experts in the appropriate field in order
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to get further requirements. These requirements are sent to the medical department which
summarized them and issues a response to the originator.
2.2.7 Coordination of the Project Requirements
The early phase of development, when attention is focussed on establishing overall
objectives, setting target design parameters and meeting PDN requirements, is a good
time to start prototyping. There are different methods to have rapid prototyping. If
designing a plastic part, methods such as Stereolithography (SLA), which is a printing
process which produces copies of solid surface models in plastic can be employed. Other
techniques like CAD/CAM and Selective Laser Sintering (SLS) are also good methods
for rapid prototyping.
Human factors should be carefully evaluated during this phase in the
development. A study conducted at Brigham and Womens Hospital in Boston in 1989
attempted to determine the causes of medical device failures within the hospital
environment over an 11-month period. The results of the study indicated 41% of the
device problems or failures were caused by user problems or errors. The misuse of a
medical device is therefore seen to have an important impact on the overall reliability of
the device. The methodology that addresses such user issues is Ergonomics or Human
Factors.
Human factors is defined as the application of the scientific knowledge of human
capabilities and limitations to the design of systems and equipment to produce products
with the most efficient, safe, effective and reliable operation.
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2.2.8 The Pre Market Notification - 510(k)
The Pre Market Notification Process 510(k) is one the regulatory pathways for device
approval. Premarket notification is documentation submitted by the manufacturer that
notifies the FDA that a device is about to be marketed. 510(k) notification assists the
agency in making a determination about whether a device is substantially equivalent to a
previous marketed predecessor device. The 510(k) premarket notification process was
designed to give manufacturers the opportunity to obtain rapid market approval of these
non critical devices by providing evidence that their device is substantially equivalent to
a device that is already marketed. The device must have the same intended use and the
same or equally safe and effective technological characteristics as a predicate device.
The decision is based on premarket notification information that is provided by the
manufacturer and includes the intended use, physical composition, and specifications of
the device.
Device Classification
In 1976, with input from the Cooper Committee, the FDA proposed the Medical
Device Amendments to the FFD&C Act, which were subsequently passed into law. The
purpose of the amendments was to assure that medical devices were safe, effective and
properly labeled for their intended use. To accomplish this mandate, the amendments
provided FDA with the authority to regulate devices during most phases of their
development, testing, distribution and use.
The Cooper Committee concluded that the many inherent and important
differences between drugs and devices necessitated a regulatory plan specifically adapted
to devices. They recognized that some degree of risk inherent in the development of
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many devices, so that all hazards cannot be eliminated. All devices were placed into
classes based upon the degree of risk posed by each individual device and its use.
Class I Devices were defined as not life sustaining, their failure poses no risk to
life, and there is no need for performance standards. Basic standards, however, such as
510(k) premarket notification, registration, device listing, good manufacturing practices
(GMP), and proper record keeping are all required. Nonetheless, the FDA has exempted
many of the simpler Class I devices from some or all of these requirements. For
example, tongue depressors and stethoscopes are both class I devices, both are exempt
from GMP. Tongue depressors are exempt from 510(k) filing, whereas stethoscopes are
not.
Class II devices were defined as not life sustained. However, they must not only
comply with the basic standards for Class I devices, but must meet specific controls or
performance standards.
Class III devices were defined in 1976 as either sustaining or supporting life so
that their failure is life threatening. For example, heart valves, pacemakers and PTCA
balloon catheters are all Class III devices.
It is necessary that the preparation of the Premarket Approval must actually begin
early in the process before it will be submitted. It is only after the company has the
results of all of the laboratory testing, pre-clinical animal testing, failure mode analysis
and manufacturing validation that their proof of safety and efficacy can begin, in the form
of a clinical study under Investigational Device Exemption.
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Types of 510()c)
There are several types of 510(k) submissions that require different formats for
addressing the requirements. These includes:
• Submissions for Identical Devices
• Submissions for Equivalent but not Identical Devices
• Submissions for Complex Devices or for Major Differences in Technological
Characteristics
• Submissions for Software-Controlled Devices
The 510(k) for simple changes, or for equivalent devices should be kept simple
and straightforward. The submission should refer to one or more predicate devices, it
should contain samples of labeling, it should have a brief statement of equivalence, and it
may be useful to include a chart listing similarities. The representation shown in figure
12 is the FDA Substantial Equivalence Process.
Submissions for complex devices or for major differences in technological
characteristics is the most difficult type of submissions, since it begins to approach the
point at which the FDA will need to consider whether a 510(k) is sufficient or whether a
Pre-Market Approval Application (PMAA) must be submitted.
As a general rule, it is often a good idea to meet with FDA to explain why the
product is substantially equivalent, to discuss the data that will be submitted in support of
a claim of substantial equivalence, and to learn the FDA's concerns and questions so that
these may be addressed in the submission.
The Food and Drug Administration
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2.2.9 The Importance of the Validation
Customer expectations and international competition have increased the pressures to
produce goods of the highest quality at a reasonable cost. Medical device products must
be safe and effective at any cost. Testing final product for compliance to predetermined
specifications is no longer enough to assure quality. One must determine and control the
quality of the raw materials for the manufacturing event and the quality of the
manufacturing process. In the complex environment of the modern manufacturing
facility with new technology products, assuring quality is a difficult task. Validation
should be designed to maximize the assurance of quality and minimize testing.
Validation, along with Good Manufacturing Practices, was mandated for the
pharmaceutical manufacturing industry in the mid-1970s in response to numerous
problems with the sterility of large volume parenterals. Prior to this time, validation had
been routinely applied only to analytical test methods in a laboratory setting. Validation
is a fundamental building block that supports corporate commitments to quality
assurance. Validation must be carefully planned to ensure that regulatory requirements
are met and that corporate philosophies are maintained in a reasonable and cost-effective
manner. Poorly planned validation and poorly understood commitments to validation can
result in excessive use of time and resources. Validation in the medical device
manufacturing is appropriate and indeed often required in order to move a product from
development to commercial production in the product life cycle. Validation confirms
that product of predetermined quality and performance characteristics can be built
reliably and reproducibly within established operating limits of the manufacturing
process at the commercial manufacturing site. Validation is the process of evaluating a
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product or a manufacturing process during, or at the end of the development process to
determine whether it satisfies specified requirements. A validation establish documented
evidence which provides a high degree of assurance that a specific product/process will
consistently produce a product/process meeting its predetermined specifications and
quality attributes. There is a section in the medical device GMP regulation that is often
cited as FDA's mandate for requiring process validation.
It is important to prepare a well-written validation protocol and report which
specifies the procedures (tests) to be conducted, the data to be collected and the analysis
that will be performed. An industry axiom says, "If it hasn't been documented, it hasn't
been done." Similarly, conclusions drawn from a poorly documented validation study
report are nothing more than corporate rumor.
2.2.10 Engineering Change Order (ECO)
The ECU is a documentation process that ensured all design or process changes have
been properly documented. The ECU package must contain all the documentation
required to define the change of the design documents which represent the item being
changed. The ECU package is usually done at the end of the development process.
For the release of a new product, the ECO should contains all the PDN
requirements, FDA clearance 510(k), validation reports, clinical evaluation reports,
manufacturing specs, packaging graphics, medical release, material specs, process
capability reports, DMR, etc. The ECO package usually gets circulated to upper
management for their approval.
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2.2.11 Product Release
The release of the product for sale is authorized when these requirements are met after
the ECO is approved.
Registration of the device with the FDA. Registration must be done when first
beginning to manufacture medical devices and must be updated yearly.
The logistics department will dictate when to start manufacture the product. They
will make sure that the products go to the appropriate distribution center. They will
be working with the manufacturing plant to review the production progress against
their schedule.
2.3 Disadvantages of the Process
Some of the disadvantages in this process is time wasted waiting for an activity to be
accomplished before proceeding to the next. In the PDN process, for example, the
originator has to wait for the requirements from the other functions after issuing the PDN.
If the originator disagrees with the requirements, PDN amendments have to be issued and
rerouted to the same reviewers. Further, with new ISO regulations emphasizing on
design control, it could make this process more cumbersome to release new products.
The product requirements usually come from marketing, who is closest to the
customer. The problem with that is these requirements are always changing, which
makes the design process longer than it should be. In the medical device world, any
change in the design, has to be documented and released through the documentation
process (i.e. ECO).
The level of documentations in the development and manufacture of medical
devices is tremendous and makes the process lengthy, specially at the early stages in the
development process. An efficient method to capture the product specifications will
reduce the development cycle time.
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CHAPTER 3
THE NEW APPROACH TO AN EFFICIENT AND TIMELY PRODUCT
DEVELOPMENT PROCESS FOR MEDICAL DEVICES
3.1 The New Approach and its Advantages
The illustration in figure 8 provides an overview of the proposed approach to product
development for medical devices. This approach evolved from the approach described in
chapter 2, with an emphasis on, the core team approach for the reduction of cycle time by
using concurrent engineering in the Attribute Driven Specifications (ADS) process for
the development of medical devices.
The purpose of this new approach is to accelerate and continually improve the
efficiency and the effectiveness of the product development for the medical device
industry. The Attribute Driven Specifications (ADS), which is the focus of the new
product development process, is discussed in details in chapter 4 of this thesis. The new
approach is also designed to fit well within the new domestic and international
regulations which are the driving force of this business. Too much control could inhibit
speedy development. The technique in this process is a fast, systematic and well
understood approach to planning, and tracking the product development history without
sacrificing overall control of the process. The International Standards Organization has
done an outstanding job of writing minimum logical requirements for a quality operation.
It is significant to note that the vast majority of the 9000 series of standards are
Document Control (ref. Watts, Engineering Documentation Control Handbook, 1993).
ISO rightfully places high emphasis on product specifications. The key nature of product
specifications is discussed throughout chapter 4.
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OVERVIEW OF PRODUCT DEVELOPMENT PROCESS FOR MEDICAL DEVICES
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Figure 8 Overview of New Product Development Process for Medical Devices
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Other advantages of this new approach are how the ADS is used to satisfy some
of the critical elements of design control. This is one of the most important elements of
the revised GMP. Some medical device manufacturers already consider the design
control program as a method for improving the product development process, while
others consider it as a necessary step to selling products in the European Community
(EC). Both the ISO and the GMP requirements call for a documented procedure to
ensure that the design requirements are properly established, verified, and translated into
design specifications.
The ADS process is an excellent method for cycle time reduction that could be
used in most parts of the design control. It is a good tool for traceability of the product
and process development. Its revision levels helps keep track of the development process
history. In comparison to the PDN process, the ADS reduces the cycle time because it
involves, at an early stage of the development process, the different functions that are
affected.
3.2 The ISO 9000 Series of Standards
IS09000 is a series of international quality standards prepared by the International
Organization for Standardization. These standards are intended to harmonize the quality
systems requirements for industries involved in the design, manufacture and international
distribution of products. In addition, revisions to the FDA Good Manufacturing Practice
Regulation for Medical Devices will require conformance to design control aspects
similar to those established in the ISO9000 series of standards.
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Further, these standards specify a quality management system. They judge how
well a business is run by their ability to deliver consistently a quality product. They deal
with all aspects of a business and how controls are managed and improved. They
describe a basic set of elements by which an organization can develop and implement a
quality management system. Registration to the series of standards is accomplished
through a third party audit by a Notified Body, which must be approved by an
international certification organization.
3.3 The Design Control
Design Control is a documented and controlled procedure to ensure the product and
process design requirements are properly established, verified, translated into design
specifications and transferred to production. Design Controls are an interrelated set of
practices and procedures that are incorporated into the design and development process.
In other words it is a system of checks and balances. Design controls make systematic
assessment of the design an integral part of development. As a result, deficiencies in
design input requirements and discrepancies between the proposed designs and
requirements are made evident and corrected early in the development process. Design
controls increase the likelihood that the design transferred to production will translate
into a device that is appropriate for its intended use.
3.4 Implementing Design Control
The fact that the medical device industry is a regulated industry. It is not always apparent
to some observers and, at times even to supplier personnel. The medical device Act of
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1976 resulted in the generation of regulations centered around the manufacturing of
Medical Devices. Justification for this action was a study performed indicating that the
majority of problems experienced by users of medical Devices were quality related, and
that these quality related problems were associated with production.
Other reasons why it is necessary to implement Design Control are:
• Domestic Regulations (FDA)
• Safe Medical Device Act of 1990
• European Regulations (European Quality System)
• ISO 9001 complemented by the particular requirements for Medical Devices in
EN46001
European focus is expected to be on the documentation of systems to comply with
the European Quality System. FDA can be expected to review the operation as well as
the documentation of the system. If, for example, a manufacturer views design control as
a means of improving the product development process, it can introduce the discipline
necessary to produce high-quality products, shorten development time, and reduce or
eliminate the annoying defects and errors that often crop up when a new product enters
full-scale manufacturing.
The up-front work expended in the ADS, establishing and evaluating the design,
conducting rigorous testing, and developing effective and efficient manufacturing
processes can pay big dividends toward meeting customer expectations, lowering
manufacturing costs, reducing liability exposure, yielding better quality products, and
increasing market penetration. The ADS is also one way to implement the design control
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in the medical device industry, it is a reference for the design specifications and therefore
control the design process from beginning to end.
The design control section of FDA's and the revised GMP regulations require
device manufacturers to establish and maintain formal controls for their product
development activities. These controls are intended to ensure that appropriate
specifications for the device are developed and thoroughly reviewed, so that the device
eventually manufactured can be used safely and effectively.
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Figure 9 Elements of Design Control
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3.5 Elements of the Design Control are Integral Parts
of the Development Process
Figure 9 shows the major elements of the design control which are: design planning,
design input, design output, design verification, design changes, and design transfer.
These elements that are described below, are now integral parts of the development
process in the medical devices industry.
3.5.1 Design Planning
The first phase of designing a new product is design and development planning, which is
described in the design control section of the International Organization for
Standardization 9001 standard. It requires manufacturers to draw up a plan that identifies
and describes the activities necessary to design and develop a device and update it as the
design evolves. Identify organizational and technical interactions that must occur among
the company's departments and its suppliers, and establish mechanisms to ensure that
necessary information is documented, transmitted, and reviewed as required.
Design and development planning makes clear what is going to happen, who is going to
make it happen, and when it will happen. Design and development planning is critical
because it establishes the groundwork for the design process.
Each description contains the assigned personnel from the Core Team and
functional team areas of responsibility. This is inter-functional requirement for each
activity. The assignment of these functions provides the indication of the input required
from each of the functions for the specified activity
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3.5.2 Design Input
The design input involves requirements relating to the device that should be specified and
documented. These requirements should address the needs of the intended user. Design
input should also include requirements for manufacturing, installation, maintenance and
servicing. Both GMP and ISO call for the technical specification in this section.
Physical and performance features and safety reliability are included. Environmental and
regulatory requirements are also addressed in this specification; and finally, labelling
requirements are part of this specification. Further, this requirement includes also, the
project proposal, the integrated project plan, the market research and the Product /Process
specifications. The resolution of conflicts, ambiguities, and incomplete requirements is
accomplished through the employment of the design reviews and during the core team
meeting.
3.5.3 Design Output
As the project progresses, product and process designs become more redefined, and the
project team begins to create product and process documentation. The design output are
documentation and specification in terms that allows an adequate evaluation of
conformance to design requirements at each stage of the design process. This phase
requires calculations, or analysis of the design to ensure that the product will meet the
design input requirements. The international requirement in this area (1S090001) is an
analytical one looking for calculations and analysis against requirement.
This phase also calls for the creation of a matrix which would list each of the
input requirements and a corresponding analytical methods used to demonstrate how the
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product will meet the input requirement. The matrix will contain the reference test
method used to demonstrate that the input requirement has been the corresponding
results. A Failure Mode Effect Analysis (FMEA) could be used in this phase to assure
product or process safety.
3.5.4 Design Verification
This part calls for planning, establish document and assign to competent personnel
functions for reviewing and verifying the design output of each activity. Design
verification shall be performed in a timely manner and shall established that design
output meets the design input requirements. A recording shall be made of the design
verification, including identification of the design verified, the date the person or the
team performing the verification.
This section also deals with the feasibility Experiments, development and test of
the demo process, molding technology development, prototypes evaluation etc...
The product and process specifications designate the verification method for each of the
requirements. The results of the verification will become part of the project file.
The formation of matrix is a systematic method of ensuring that all input requirements
are addressed.
3.5.5 Design Changes
This section calls for the review, evaluation, approval and documentation of all changes
to the design during the development. While all proposed changes need not to be
documented, all approved changes for incorporation into the design must be documented
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and controlled. This section also calls for control documentation. Written procedure
shall be established, implemented and controlled for the identification, review and
approval of design changes. At appropriate intervals and at the conclusion of the design
process, a formal systematic and documented review of the design results shall be
conducted to assure the design meets the design input requirements. Design review shall
include designated individuals representing all functions affecting quality. A written
record of the design reviews shall be made.
3.5.6 Design Transfer
Activities that result in documentation that initiate a transfer from development to
production would have to be reviewed to ensure they meet the intention of the proposed
GMPs/ISO. They are validation, pilot study, molding technology, clinical for product
validation, process validation labeling and packaging.
The design control concepts are applicable to process development as well as
product development. The extent is dependent upon the nature of the product and
process used to manufacture the product. The safety and performance of a new product is
also dependent on an intimate relationship between product design robustness and
process capability.
CHAPTER 4
THE ATTRIBUTES DRIVEN SPECIFICATIONS APPROACH
4.1 Introduction to the Attribute Driven Specifications Process
At the start of the development we attempt to capture the customer needs in a document
often called product specification. This sounds simple enough but is actually a stumbling
point for many medical device product developers, and the consequences of poorly
written specifications show up as lost of time later in the project. Specifications provide
input that is critical to both the product and the development process. The technique
covered in this chapter will help avoiding writing specifications slowly or producing ones
that are slow to win approval.
According to Haynes (ref. MDDI 1993), there is an approach to project
communication that has been shown to work, and work effectively. It provides guidance
from the start and avoids most conflict as the project progresses to completion. It is
called Attribute-Driven Specification (ADS).
With the rapid design cycle inherent in Concurrent Engineering, effective
specifications are needed at the outset of a project. Without early resolution of the target
specifications, the project will suffer form communication problems. Confusion about
the desired path to the goal is unavoidable.
This is a good tool to use in the development of medical device products. It could
also be used to track product history by maintaining revision levels. The ADS is a good
way to implement the Design Control of the project.
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4.1.1 Definitions
o Attributes are customer descriptions of product characteristics.
o Engineering Parameters are a set of measurable, physical properties defining
atti	 ibutes.
o Specifications are sets of detailed and exact statements of requirements.
o Needs are features must be in the product.
o Wants are features that will help differentiate the product from competitors.
o Desires are innovative features that will appeal to the customers.
o Internal customers are any person or department within the company who is
provided with a product.
o External customers are any person or organization outside the company who
is provided with a product.
o Ideal performance level is the point beyond which little market value is
achieved for the effort and risk involved.
o Limit performance level is the negotiated, absolute worst acceptable
performance for the parameter which it is believed the customer will accept,
assuming all other parameters are at goal.
o Goal performance level is the best estimate of achievable performance within
the agreed upon ideal and limit performance levels.
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4.2 Communication is Essential for Product Specification
As we know, Concurrent Engineering will not work without excellent communication
among all parties, for beginning to end. Bad communication had been known as one of
the main issue between Engineering, Marketing, Medical etc.
Numerous methods of obtaining new product information for medical devices exist.
They include various ways of collecting data, such as internal sources, industry analysis,
and technology analysis. The information is screened and a business analysis is
conducted. The Quality Function Deployment (QFD) is a process where the voice of the
customer is first hand in could be related to the process discussed in this chapter.
4.3 The QFD Approach
The QFD process has been applied for many years in different businesses including
medical devices (ref. Akao, Yoji 1988). The Ford Company defines QFD as a planning
technique for translating the customer's required quality characteristics into appropriate
product or services features. QFD was developed in 1966 in Japan, and one of the first
applications was credited in the early 1970s by Mitsubishi Heavy Industries. QFD is a
systematic process which establishes customer requirements and accurately translates
them into the appropriate technical design, manufacturing and production planning
requirements. QFD is a matrix-based methodology which is effective in the hands of an
experienced cross-functional team. The basic matrix of the QFD is the house of quality.
It is called a house because of its shape, although it can look quite different if a large
quantity of data is analyzed. QFD in many ways resemble the ADS process described in
this chapter.
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4.4 Difficulties in Writing Specifications
One complication in writing specifications is that many types of knowledge are needed,
Engineering, Medical, Marketing, Quality, Regulatory Affairs and Manufacturing, to
name a few. They will define the product and develop it. This means that all these
different functions must interact to share information and reach a mutually satisfactory
solution. One danger is having separate specifications. For example, marketing could
write specifications from the sales and business perspectives, engineering could write
about specifications that describes how the product is to work in considerable detail, and
manufacturing could later try to interpret these specifications to produce what they
thought the customer wanted.
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Figure 10 The Attribute Driven Specifications Process
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4.5 Requirements for Writing an Effective Specification
First and foremost, the specification must be the customer's voice to the development
team. It must interpret the market needs which is to be filled by the product under
development and it must define the project goal without ambiguity and in a verifiable
way which guides design yet allows tradeoffs. It must point to a product goal which is
competitive yet achievable, balancing risk vs. return, guiding all members of the product
development team to pull in the same direction.
4.6 The Attribute Driven Specification
All project or product specifications contain two key columns: the parameter to be
specified and a valued to be achieved. If the specification is describing an evacuated
blood collection tube, for example, the parameter might be blood volume with the value
to be achieved 5 mL. This attention on engineering parameters is specific, clear and
measurable, but often isolates the designer from the motivation behind the goal.
Customers do not buy parameters, they select, differentiate and buy products based on
attributes and their needs, wants, and desires. In our example of blood volume as the
parameter, it is linked to the attribute cost.
Attributes are the customer's voice in the attribute-driven specifications (ADS).
Each design parameter is related to an attribute desired by the customer; this ensures that
the development will have a market-driven focus.
A major addition of the ADS is the use of the three levels of performance for each
parameter; the design goal is bracketed by two other levels; an ideal performance level
and a minimum acceptable limit. Figure 10 illustrates the ADS process.
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4.7 Creation of an ADS Step by Step
There are four defined stages in the process of developing and using the ADS: identify
the elements, link them, negotiate the performance levels, and review progress.
Stage1-Identify the Key Elements
The task:
	 What is the proposed project and who is the customer
The Team:	 Who will be involved from each major functional group: R&D,
Engineering, Manufacturing, Marketing, Medical, Regulatory Affairs, Quality Assurance
The Mission: What is the project target? E.g. define, develop, and deliver a safety next
generation needle which could capture 20% of the regular needle in the market by
December 1999 with a projected return on investment of 30% or more.
The Attributes:	 What are the key customer needs? This could be anything from
quality, ease of use etc.
The Parameters: What are the Engineering/Scientific parameters which define the
performance attributes.
Stage 2-Link the Parameters and Attributes
Tie each parameter to an attribute and vice versa. Add additional parameters and/or
attributes until all are linked. Parameters not linked to an identified attribute should be
questioned.
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Stage 3-Negotiate the Three Performance Level
This is the key stage. The successful completion of the project will be determined by
these decisions. The team must reach a consensus on the three levels of performance for
each parameter. At this stage, engineering could initiate the early negotiation with
manufacturing for example, medical and regulatory affairs, etc.
Stage 4-Review Progress, Goals and Limits
As the project progresses, the Project Team should refer to the ADS in each regular
project review. The Technical Team members should regularly update the Goal, always
within the ideal and limit levels. The Marketing Team members may occasionally
negotiate adjustments in the ideal or limits levels as external conditions change. With a
well-designed ADS, participation by senior management may be unnecessary at this
stage. Figure 11 illustrates the four stages of the ADS process.
Creation of an ADS
Stage 1 	 Stage 2 Stage 3 	 Stage 4
Team
Limits
Atributes
Mission
Attributes
Parameters
Ideal
Identifiy Key Elements Link Parameters and
Attributes
Negotiate Three
Performance Level Review Progress
Task Parameters Limits Goal
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Figure 11 Creation of an ADS Step-by-Step
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4.8 Practical Suggestions for using the ADS Method
Identifying and linking attributes to parameters is demanding work. Several keys for
stimulating this process are helpful. First, the general categories of attributes, utility,
safety, etc. in the ADS help stimulate the team and organize their thoughts. The customer
will place different weighting on these categories throughout the product life cycle.
The team should sort out the hierarchy of the attributes for the proposed product. Some
attributes will be necessary to be a player in the market. Others attributes will be the
basis of competition, the means of differentiating products, features which play to
customer wants. The very innovative features and leaps in performance will appeal to
customer desires.
During the negotiation of Stage 3, the hierarchy can serve to highlight the degree of
flexibility which can be afforded in setting levels. Parameters linked to needs can seldom
be compromised, those linked to wants can be more flexible, and those associated with
customer desires can be afforded the greatest latitude.
In negotiating the limit performance level for a parameter in the desire grouping,
it is important to assume that all other parameters are at their goal level, and push as hard
as possible on the limit level, to find the absolute minimum acceptable performance.
Only by providing this room for design tradeoffs will the marketing team members give
the engineering team the flexibility to insure successful completion of the project. This
approach minimizes the overall project risk by balancing the risks of market failure vs.
technical failure.
The Attributes-Driven Specification approach ties together the process from
attribute to parameter to specification; guiding design tasks, manufacturing process, and
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maintaining market competitiveness while preserving flexibility for design tradeoffs.
With a well define and negotiated ADS, with consensus on three level performances,
there will be few surprises as the project progresses if the team participates in regular
reviews.
Where consensus cannot be reached, the group may have chosen a project beyond
their ability to deliver, and management needs to reconsider the fit with the group's
mission.
Unlike other approaches, the three level method keeps flexibility for design
tradeoffs, instead of setting up specifications "cast in concrete". Also, unlike other
approaches, the ADS method insists on early and meaningful participation by
management.
4.9 Who Should Sign the ADS?
One of the most debated issue in the change control system is the signature requirements.
Everyone wants to sign. This is one of the biggest contributors to long throughput time.
The ADS should be signed by the people the closest to the action; it should be signed by
the core team, leader and members. If a Core Team member thinks he is not up to par to
sign the document, it is his responsibility to seek the appropriate person, such as his
functional manager, to sign the document. Doing so, reduces the cycle time of generating
and issuing specifications and start the design control for the product.
The illustration in figure 11 shows a reduction in cycle time with the ADS
approach.
Figure 12 Product Development Cycle Time
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CHAPTER 5
EXAMPLE OF THE CURRENT PROCESS
5.1 The Need for a New Product
The example given in this chapter is for the development of a new medical device
product that is being developed by Becton Dickinson Vacutainer Systems (BDVS)
Division, where the tools described in chapter 3 for the new approach were used. This
example is the best that could fit this model, although not every part of the process was
used. The ADS approach used in this project resulted in a release of a high quality
product for sale in less time than using the conventional product development process.
The concept of the new product came from market research, by talking to the
customer (laboratory technician) to find out what BDVS could do to improve the
efficiency in the lab. Out of all the requests, one seems that could fit the business
strategy more than the other. It is a need for a secondary tube that is used in the clinical
laboratory.
The current laboratory work flow for analytical blood testing after the physician
had ordered a test for a patient is as follows.
• The blood is drawn from the patient into an evacuated collection tube.
• The tube is than labelled with the patient ID.
• The tube is sent to the lab for testing (i.e. chemistry).
• Upon arrival of the collection tube, it is re-labelled properly with the patient
identification.
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• The technician confirms that the blood is clotted, and then places the tube in the
centrifuge.
• After centrifugation, the tube is removed for the cup, there is now three different
layers of separation in the tube. The red cells are located at the bottom of the tube,
the gel is in the middle and the serum is at the top of the tube. The serum is what the
technicians need to perform the test.
• Laboratory technicians usually pour off or pipette the serum sample into a secondary
tube allowing for simultaneous testing of the primary sample.
The lab technicians use different secondary tubes with any closure that could fit.
They are usually closed with a plug-type closure that must be removed before placement
on analyzers, since most analyzers do not have cap-piercing abilities. Upon removal
from analyzers, these tubes are often recapped with another closure. Hence the lab
technician usually uses two closures per tube, because once removed, the closure is
discarded for contamination purposes.
The vision of BDVS is to become the industry leader in specimen management,
thereby becoming more integrated into the diagnostic processing chain. After evaluating
this opportunity, BDVS wanted to commercialize a value-added secondary tube that
replaces existing products and meets the needs of the existing manual and emerging
automated lab markets. The new secondary Tube and Closure product will be a unique
value-added offering that will differentiate BDVS in this large niche market. The new
design is an integrated closure. The illustrations in figures 13, 14, and 15 give a pictorial
view of the new product that was developed based upon the need of the technicians. The
example given in this chapter will address how the ADS was a valuable tool in the
development of this new product.
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Figure 13	 BDVS Next Generation Secondary Tube with Closure
0 Becton Dickinson, 1996
Figure 14
	 BDVS Next Generation Secondary Tube with Closure
© Becton Dickinson, 1996
65
Figure 15 	 Next Generation Secondary Tube with Closure
© Becton Dickinson, 1996
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5.2 The Product Development Process
A Core Team leader, who came from the R&D functional group, was elected by the
upper management. The Core Team members were carefully selected as discussed in
chapter 2, with representatives from, Medical, Marketing, Manufacturing, Quality
Assurance, R&D and Process Technology. An aggressive project plan was developed by
the team and presented to the upper management.
5.3 The Development of the ADS
The attributes for the product came from market research and discussion with many
customers, ease of use, automation friendly, safe, specimen quality and cost to name a
few. Since this is the end-user attributes for the new product, the core team met to
discuss how to design a product that could meet all these attributes. Some of the
parameters for ease-of-use were defined as specimen transfer without closure removal;
easy transfer from primary tube; easy manual operation and positive lock confirmation
for open and close. The parameters for automation friendly were as follow: compatible
with existing closure; bar code label compatibility; physical dimensions compatible with
transport activities (carousel, rack, track); ability to recognize specimen; and compatible
with automated closure operation. The parameters for safety were defined as: Ability to
withstand an accidental drop within lab; closure functionality after multiple cycles and
after freeze and thaw; ability to centrifuge the product; specimen should not leach; the
ability to withstand world wide shipping conditions prior to use.
After the Core Team has reached a consensus on the design parameters, they then
negotiated the different levels of specifications. The focus at first was on the end-user
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attributes. Then the other requirements from the internal customers were developed. The
ideal performance level is to have a high-speed process for assembling the finished
molded plastic parts and then pack them. The design goal is to have a semi-automated
process, and minimum acceptable limit is a manual process. The manufacturing
requirements were to have a validated one-cavity mold for each component at initial
release and then validate a high cavitation (64 cavities) in order to reduce the
manufacturing cost.
The marketing requirements were similar to the end-user requirements, since for
the most part they represented the external customer in the development process. One
limitation was to conduct an end user assessment before the release of this product for
sale. The three level specifications could be used for the marketing requirements with
respect to the product sales price. The priced are justified because the current product
sells for $0.04 - $0.06 for one tube and a closure, and multiple closures are generally
used. This wasted expense is eliminated by the new design. The medical requirements
were straight forward, since this is a secondary product, it has no contact with the patient
and so no clinical evaluation was necessary. The Quality Assurance requirements were
to validate the molding process to show its true capability and reliability. The Regulatory
Affairs goal was no 510 (k) since this a class 1 device. The R&D requirements were to
meet most of the attributes from ADS of the End User.
The internal customers of the ADS were not in the same scale as the external
customers. The illustration in the Table 4 shows in detail all the attributes of the product
and the engineering parameters. The last column of the table displays the current status
of the parameters.
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After developing this ADS, it was easy to implement the plan. The communication was
good among all parties since all the specifications and requirements were developed by
the same team. The ADS was used as good design control, because the revision level
was kept, and also the rationale for each change was documented. The Core Team
members signed the ADS since they were the one the closet to the project.
The cycle time for the product development was not extensive when compared to
others. The work that was done up-front with the ADS made all the difference. All the
product requirements and specifications were known early on since the functions in the
organization that will dictate the requirements were part of the team, therefore each
person knows, which direction the product/process was going and was able to discuss and
negotiate on requirements or specifications.
During the product development process the team identified three reference
laboratories that were willing to evaluate the product for us. This End User Assessment
was one of the most important part of the development process as it validated the ADS.
The customers were able to work with the product and tell us their opinion of the product
in their own word. In conclusion, not all of the ADS requirements were met, 75% met
the goal and the limit, but the customer loved the product and wanted to start purchase it.
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Figure 16 Phase Approach
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5.4 The Phase Approach
The diagram in figure 16 shows another way of looking at the new approach by dividing
it into four phases. Phase I is the conceptual phase: market research, project proposal,
selection of the Core Team and product registration. Phase II is the design phase: the
creation of the ADS, rapid prototyping, and initiation of the design control. Phase III is
the development phase: design freeze, one-cavity mold validation, documentation release
through ECO process, clinical testing, physical performance and market trial. Phase IV is
the release phase: product launch, high cavitation production mold, process capability
and high-speed assembly.
CHAPTER 6
CONCLUSION
Developing a new product is unique every time. Even if the product is the same the
project would have been different, the team would have been different, the learning curve
would have been different. The development cycle time is generally considered to be the
elapsed time from initial product concept until new product is commercially available.
The period of interest to us in this thesis is shown in figure 8. Getting a new product to
market in advance of the competition has the obvious advantage of capturing additional
sales and higher profit margins, assuming the product meets a need not otherwise met by
existing products. Competitive and market concerns increasingly force companies to set
more aggressive development cycle times.
The value of the Alit	 ibute Driven Specifications approach in the development of
medical devices is significant. The example provides in Chapter 5 shows how efficient
and quick the development process for a new medical device is by using the approach.
The term effective means doing the right things; in this case, designing a medical
device that, once manufactured and delivered, will exceed customer expectations while
meeting company objectives with respect to revenues, profits or market shares.
Continuous Improvement seems destined to dominate the world of business for
years to come. In an environment of dynamic global competition, manufacturing
companies that are today's industry leaders do not retain their industry position unless
they get increasingly better at all value-added activities and are increasingly productive
by paring down other overhead activities. Those who are not aggressive leaders must
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embrace this philosophy if they are to survive, and they must do so with vigor if they are
to have a chance of attaining and sustaining a viable position in their chosen markets.
Improving the design and development processes of new medical device products
has moved upward on the agenda of most manufacturers. Improvement efforts are
widespread and have gone on long enough for many companies to see real differences in
their process and their results.
Managing across organizational boundaries becomes especially challenging in a
global context. This is as true for widely dispersed plants or engineering groups in a
single company as for external suppliers from another country. Agreeing in advance on
the purpose and desirable extent of this interaction is a good place to start.
There is no reason to believe that the pressure for speed to market coupled with increased
quality and customer satisfaction and reduced product cost will subside in the foreseeable
future.
In summary, cutting lead-time and increasing customer satisfaction for medical
devices require strengthening a company's capability for horizontal integration, so that a
cross-functional team can work effectively and productively toward a common end.
The capability to develop new products rapidly and efficiently is a powerful source of
competitive advantage. The Attribute Driven Specifications approach explained in this
thesis gives some guidelines to be more efficient in the product development process of
medical devices. Various business strategies call for a different emphasis in the design
and development of products, and a company's business strategy ought to be compatible
with its distinctive competence in the introduction of new products.
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